The purpose of this study is to understand how the different formulation of phenytoin is taken up into the blood in Healthy Adults. This study is seeking healthy adult participants. All the study participants will receive Phenytoin 50 mg chewable tablets manufactured at Ascoli and Vega Baja manufacturing site. We will measure how the phenytoin will be taken up into the blood in Healthy Adults following oral dosing of Phenytoin. This will help us determine if the Phenytoin 50 mg chewable tablets manufactured at Ascoli and Vega Baja manufacturing site are similar or not.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Enrollment
35
Phenytoin 50mg chewable tablets
Phenytoin 50mg chewable tablets
Pfizer Clinical Research Unit - New Haven
New Haven, Connecticut, United States
Area Under the Plasma Concentration-time Profile From Time Zero to the Time of Last Quantifiable Concentration (AUClast)
Time frame: 72 hours
Maximum Observed Plasma Concentration (Cmax) of Phenytoin
Time frame: 72 hours
Number of Participants With Adverse Events (AEs) According to Seriousness
Time frame: Baseline, up to 35 days post last dose.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.